TY - JOUR
T1 - Tumor infiltrating lymphocytes in early breast cancer
AU - Pruneri, Giancarlo
AU - Vingiani, Andrea
AU - Denkert, Carsten
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Immunoediting represents a complex and dynamic process involving cancer and immune system cells, composed by three intertwined phases: elimination, equilibrium and escape. A large number of immune cell subtypes are involved, each playing a peculiar role in interacting with cancer cells: cytotoxic CD8+ T cells play a main role in cancer killing by inducing tumor cell death, while FOXP3+ T-regulatory cells represent an immune-inhibitory cell subtype. The evaluation of tumor infiltrating lymphocytes (TILs) in H&E routine samples has been shown to represent a reliable surrogate of the immune anti-tumor activity and a robust independent prognostic biomarker in breast cancer (BC) patients, especially in the Tripe Negative and HER2+ subtypes. The present review addresses the mechanisms of breast cancer immunoediting, its cell complexity and prognostic/predictive relevance, providing evidence that TILs represent one the most promising biomarkers for BC patients.
AB - Immunoediting represents a complex and dynamic process involving cancer and immune system cells, composed by three intertwined phases: elimination, equilibrium and escape. A large number of immune cell subtypes are involved, each playing a peculiar role in interacting with cancer cells: cytotoxic CD8+ T cells play a main role in cancer killing by inducing tumor cell death, while FOXP3+ T-regulatory cells represent an immune-inhibitory cell subtype. The evaluation of tumor infiltrating lymphocytes (TILs) in H&E routine samples has been shown to represent a reliable surrogate of the immune anti-tumor activity and a robust independent prognostic biomarker in breast cancer (BC) patients, especially in the Tripe Negative and HER2+ subtypes. The present review addresses the mechanisms of breast cancer immunoediting, its cell complexity and prognostic/predictive relevance, providing evidence that TILs represent one the most promising biomarkers for BC patients.
KW - Breast cancer
KW - Gene expression
KW - Phenotype
KW - Prognosis
KW - Tumor infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85016791341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016791341&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2017.03.010
DO - 10.1016/j.breast.2017.03.010
M3 - Article
AN - SCOPUS:85016791341
VL - 37
SP - 207
EP - 214
JO - Breast
JF - Breast
SN - 0960-9776
ER -